Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
BLRX 
BioLineRx Ltd (BLRX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/18/2025: BLRX (3-star) is a REGULAR-BUY. BUY since 20 days. Profits (25.90%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
2 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $26
Year Target Price $26
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 52.27% | Avg. Invested days 25 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 06/18/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.48M USD | Price to earnings Ratio - | 1Y Target Price 26 |
Price to earnings Ratio - | 1Y Target Price 26 | ||
Volume (30-day avg) - | Beta 0.9 | 52 Weeks Range 2.30 - 35.60 | Updated Date 06/29/2025 |
52 Weeks Range 2.30 - 35.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -15.21% | Operating Margin (TTM) -937.65% |
Management Effectiveness
Return on Assets (TTM) -21.98% | Return on Equity (TTM) -20.03% |
Valuation
Trailing PE - | Forward PE 109.89 | Enterprise Value 3810269 | Price to Sales(TTM) 0.74 |
Enterprise Value 3810269 | Price to Sales(TTM) 0.74 | ||
Enterprise Value to Revenue 0.17 | Enterprise Value to EBITDA 0.45 | Shares Outstanding 3721000 | Shares Floating 2139457835 |
Shares Outstanding 3721000 | Shares Floating 2139457835 | ||
Percent Insiders 4.08 | Percent Institutions 0.22 |
Analyst Ratings
Rating 4.5 | Target Price 26 | Buy 1 | Strong Buy 1 |
Buy 1 | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
BioLineRx Ltd
Company Overview
History and Background
BioLineRx Ltd. is a biopharmaceutical company focused on oncology. Founded in 2003, it initially in-licensed and developed clinical-stage therapeutic candidates, and later focused on developing its own assets. A key milestone was the FDA approval of Aphexda (motixafortide) in 2023.
Core Business Areas
- Oncology: Developing and commercializing therapies for hematological cancers and solid tumors. Core focus is on Aphexda (motixafortide), a CXCR4 inhibitor.
Leadership and Structure
The leadership team includes seasoned executives with experience in pharmaceutical development and commercialization. The organizational structure is typical of a small-cap biopharmaceutical company, with functional departments focusing on R&D, clinical development, regulatory affairs, and commercial operations.
Top Products and Market Share
Key Offerings
- Aphexda (motixafortide): A CXCR4 inhibitor approved by the FDA for use in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. Market share is currently small due to recent launch, but has significant potential. Competitors include stem cell mobilizers, such as plerixafor (Mozobil) from Sanofi.
Market Dynamics
Industry Overview
The biopharmaceutical industry, specifically in oncology, is characterized by intense competition, high R&D costs, and a complex regulatory landscape. The stem cell mobilization market is driven by the increasing incidence of hematological malignancies and the growing demand for autologous stem cell transplantation.
Positioning
BioLineRx is positioned as a company with an approved product (Aphexda) in the stem cell mobilization market, seeking to capture market share from existing treatments. Its competitive advantage lies in Aphexda's efficacy and safety profile in clinical trials. Its pipeline is limited at this time, but they are working on further developing Aphexda.
Total Addressable Market (TAM)
The global stem cell mobilization market is projected to reach several billion USD. BioLineRx's TAM is a subset of this, specifically the multiple myeloma autologous stem cell transplantation segment. Their success depends on the adoption rate of Aphexda.
Upturn SWOT Analysis
Strengths
- FDA approved product (Aphexda)
- Targeted therapy for a specific market
- Experienced leadership team
- Strong clinical trial data for Aphexda
Weaknesses
- Limited product portfolio
- Reliance on a single product
- Small market capitalization
- Need for additional funding
Opportunities
- Expanding Aphexda's indications to other hematological malignancies
- Partnerships with larger pharmaceutical companies
- Geographic expansion
- Further clinical development of Aphexda in combination therapies
Threats
- Competition from existing stem cell mobilizers
- Regulatory hurdles
- Reimbursement challenges
- Clinical trial failures
Competitors and Market Share
Key Competitors
- SNY
Competitive Landscape
BioLineRx's advantages include Aphexda's efficacy in clinical trials. Disadvantages include its small size and limited resources compared to larger pharmaceutical companies like Sanofi (SNY).
Growth Trajectory and Initiatives
Historical Growth: Historically, BioLineRx experienced limited growth due to lack of approved products.
Future Projections: Future growth is highly dependent on the successful commercialization of Aphexda. Analyst estimates vary but generally project revenue growth.
Recent Initiatives: Recent initiatives include the launch of Aphexda, expanding its commercial team, and pursuing potential partnerships.
Summary
BioLineRx is a company focused on commercializing Aphexda, approved to treat multiple myeloma. The company will need to successfully launch Aphexda and create new partnerships for continued growth. A small market capitalization and single product focus make it somewhat risky. Future growth will depend on how Aphexda fares in the market.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- Company Website
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About BioLineRx Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2011-07-25 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 28 | Website https://www.biolinerx.com |
Full time employees 28 | Website https://www.biolinerx.com | ||
BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.